… approved RNA therapies being used to treat patients today. Axiomer™ RNA editing technology Axiomer™ RNA editing … RNA oligonucleotides to alter RNA. We call this technology Axiomer™. We believe this technology has the potential to …
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
… An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology. We are ProQR We are … and common diseases. We focus on advancing our proprietary Axiomer™ RNA-editing platform technology. ProQR has offices …
… treatments for people with rare genetic diseases. Axiomer RNA base editing At ProQR we invented the Axiomer™ technology that enables single base editing to …
… and families affected by rare and common disorders using Axiomer, our innovative RNA editing platform technology. At … and families affected by rare and common disorders using Axiomer, our innovative RNA editing platform technology. …
At our offices in Leiden we are advancing our proprietary Axiomer RNA-editing platform technology. Our ProQRians, representing over 30 nationalities, are passionate and driven to change the lives of patients and their loved ones.
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to … for cardiovascular diseases, and progress made across the Axiomer platform €89.4 million cash and cash equivalents as …
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … perspective in guiding the Company in the translation of Axiomer, our leading RNA editing platform technology, to the …
